The DOI matches its Crossref record; 109 of the 110 references it cites were found in a registry or an index.
CAR-T cell therapy: current limitations and potential strategies
Open accessAbstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To address this, various immunotherapeutic strategies have emerged, including adoptive cell transfer, primarily utilizing genetically modified T cells expressing chimeric antigen receptors (CAR T-cells) to recognize and eliminate cancer cells directly (Sterner and Sterner, 2021). Adjuvant therapies, such as dendritic cell, mRNA, and peptide-based vaccinations, aim to boost the patient’s anticancer”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Research works printed but not linked: 1
- Peter P. Lee (eds.) Tumor Microenvironment (Springer) https://www.springer.com/gp/book/9783030388614
Cited by
Sorted by citations
Items 601–700 of 1,002
Nie, S., Song, Y., Hu, K., Zu, W., Zhang, F., Chen, L., Ma, Q., Zhou, Z., & Jiao, S. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2358590 · Cited by 22
The future of immunotherapy for diffuse large B‐cell lymphoma
Duell, J., & Westin, J. R. (2024) · International Journal of Cancer · doi:10.1002/ijc.35156 · Cited by 22
New treatment strategies in Myasthenia gravis
Attarian, S. (2024) · Revue Neurologique · doi:10.1016/j.neurol.2024.09.006 · Cited by 23
Advances in preclinical and clinical studies of oncolytic virus combination therapy
Du, W., Na, J., Zhong, L., & Zhang, P. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1545542 · Cited by 24
Füchsl, F., & Krackhardt, A. M. (2022) · Cells · doi:10.3390/cells11030410 · Cited by 24
Exploring the depths of IgG4: insights into autoimmunity and novel treatments
Ünlü, S., Navarro, B. G. S., Çakan, E., Berchtold, D., Hanna, R. M., Vural, S., Vural, A., Meisel, A., & Fichtner, M. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1346671 · Cited by 23
The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer
Liu, C., Qifeng, J., & Shaolei, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01117-7 · Cited by 22
Maintaining the Balance: Regulation of NK Cell Activity
Imširović, V., Wensveen, F. M., Polić, B., & Jelenčić, V. (2024) · Cells · doi:10.3390/cells13171464 · Cited by 31
Giurini, E. F., Ralph, O. G., Pappas, S. G., & Gupta, K. H. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0311 · Cited by 25
Cardiovascular toxicities associated with novel cellular immune therapies
Munir, M., Sayed, A., Addison, D., & Epperla, N. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013849 · Cited by 27
Immunotherapy for gastric cancer: Advances and challenges
Zhang, P., Zhang, C., Li, X., Chang, C., Gan, C., Ye, T., & Cao, D. (2024) · MedComm – Oncology · doi:10.1002/mog2.92 · Cited by 21
Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer
Kutle, I., Polten, R., Stalp, J. L., Hachenberg, J., Todzey, F., Hass, R., Zimmermann, K., von der Ohe, J., von Kaisenberg, C., Neubert, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1485461 · Cited by 24
Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting
Zhu, D., Kim, W., Lee, H., Bao, X., & Kim, P. (2025) · Advanced Materials · doi:10.1002/adma.202414882 · Cited by 24
Jun, an Oncological Foe or Friend?
Jafri, Z., Li, Y., Zhang, J., O’Meara, C. H., & Khachigian, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020555 · Cited by 22
Sun, X., Zhang, Z., Zhao, W., Xu, S., Zhang, J., ZhuanSun, X.-M., Ye, J., Han, Y., Gu, Z., & Chen, Z. (2025) · Small · doi:10.1002/smll.202503384 · Cited by 23
Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells
Li, Y.-R., Hu, J., Li, Z., Zhu, E., Chen, Y., Halladay, T., Shen, X., Fang, Y., Zhu, Y., Lyu, Z., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102321 · Cited by 24
Targeting metastasis with nanomedicine
Pallares, R. M., Consolino, L., Wang, A., Lorenzi, F. D., Kiessling, F. M., Schroeder, A., & Lammers, T. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00358-7 · Cited by 28
Castelli, S., Wilson, W. V., Uslu, U., Finck, A., Rommel, P. C., Assenmacher, C., Atoche, S. J., Siurala, M., Aznar, M. A., Young, R. M., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.021 · Cited by 21
Köseer, A. S., Loureiro, L. R., Jureczek, J., Mitwasi, N., Soto, K. E. G., Aepler, J., Bartsch, T., Feldmann, A., Kunz‐Schughart, L. A., Linge, A., et al. (2022) · Cancers · doi:10.3390/cancers14071677 · Cited by 21
Ying, Z., Song, Y., & Zhu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.834113 · Cited by 21
Priyadarshini, S., Harris, A. H., Treisman, D., Cupac, J. N., Li, N., Yan, D., & Munker, R. (2022) · American Journal of Hematology · doi:10.1002/ajh.26668 · Cited by 21
Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
Teppert, K., Wang, X., Anders, K., Evaristo, C., Lock, D., & Künkele, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314563 · Cited by 26
Flores-Torres, S., Jiang, T., Kort-Mascort, J., Yang, Y. K., Peza-Chavez, O., Pal, S., Mainolfi, A., Pardo, L. A., Ferri, L. E., Bertos, N., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00998 · Cited by 25
CRISPR-Cas9 base editors and their current role in human therapeutics
Lahr, W. S., Sipe, C. J., Skeate, J. G., Webber, B. R., & Moriarity, B. S. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2022.11.013 · Cited by 21
Labat‐de‐Hoz, L., Rubio-Ramos, A., Correas, I., & Alonso, M. A. (2023) · Cancers · doi:10.3390/cancers15102801 · Cited by 21
Poorebrahim, M., Quiros‐Fernandez, I., Marmé, F., Burdach, S. E. G., & Cid-Arregui, Á. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216242 · Cited by 21
Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma
Shu, L., Tang, J., Liu, S., & Tao, Y. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00883-w · Cited by 21
Recent advances and current challenges in CAR-T cell therapy
Joy, R., Phair, K., O’Hara, R., & Brady, D. B. (2023) · Biotechnology Letters · doi:10.1007/s10529-023-03461-0 · Cited by 21
The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Xiong, Q., Wang, H., Shen, Q., Wang, Y., Yuan, X., Lin, G., & Jiang, P. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05101-1 · Cited by 21
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sheikhlary, S., Lopez, D. H., Moghimi, S., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14040503 · Cited by 22
CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions
Abraham, A. R., Maghsoudlou, P., Copland, D. A., Nicholson, L. B., & Dick, A. D. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1184937 · Cited by 20
4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20
Dou, Z., Bonacci, T., Shou, P., Landoni, E., Woodcock, M. G., Sun, C., Savoldo, B., Herring, L. E., Emanuele, M. J., Song, F., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01198-y · Cited by 20
Zhen, X., Kim, J., Kang, J. S., Choi, B. J., Park, K. H., Lee, D., Hong, S., & Lee, J. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105390 · Cited by 20
Zhou, Z., Chen, Y., Ba, Y., Xu, H., Zuo, A., Liu, S., Zhang, Y., Weng, S., Ren, Y., Luo, P., et al. (2024) · Cell Proliferation · doi:10.1111/cpr.13791 · Cited by 20
CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models
Zhi, L., Zhang, Z., Gao, Q., Shang, C., He, W., Wang, Y., Guo, C., Niu, Z., & Zhu, W. (2025) · BMC Cancer · doi:10.1186/s12885-025-13780-2 · Cited by 20
A narrative review: Ultrasound-Assisted drug delivery: Improving treatments via multiple mechanisms
Tao, W., Lai, Y., Zhou, X., Yang, G., Wu, P., & Yuan, L. (2025) · Ultrasonics · doi:10.1016/j.ultras.2025.107611 · Cited by 20
Sun, N., Wang, C., Edwards, W., Wang, Y., Lü, X., Gu, C., McLennan, S., Shangaris, P., Peng, Q., Mastronicola, D., et al. (2025) · Advanced Science · doi:10.1002/advs.202416066 · Cited by 22
Tailoring CAR surface density and dynamics to improve CAR-T cell therapy
Hinckley-Boned, A., Barbero-Jiménez, C., Tristán‐Manzano, M., Maldonado‐Pérez, N., Hudecek, M., Justicia-Lirio, P., & Martı́n, F. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010702 · Cited by 20
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma
Masouleh, S. S., Nasiri, K., Ravari, A. O., Rad, M. S., Kiani, K., Sultani, A. S., Nejati, S. T., & Nabi‐Afjadi, M. (2025) · Biomarker Research · doi:10.1186/s40364-025-00783-1 · Cited by 21
Liu, W., Jing, Y., Yang, C., Sun, H., Xu, W., Liang, R., Liu, W., Zhang, Z., & Liu, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1581951 · Cited by 23
Metallic nanomedicine in cancer immunotherapy
Li, S., Wang, X., Han, H., Xiang, S., Li, M., Long, G., Xia, Y., Zhang, Q., & Li, S. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.017 · Cited by 21
Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer
Guirguis, D. A., Hasan, F. N., Morris, N., Alabd, A., Tawfik, P. M. S., Pramanik, K. C., & Pandey, M. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152411 · Cited by 22
Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma
Kisseberth, W. C., & Lee, D. A. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.672361 · Cited by 22
Therapeutics to harness the immune microenvironment in multiple myeloma
Ignatz-Hoover, J. J., & Driscoll, J. J. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.23 · Cited by 21
Mukherjee, P., Park, S. H., Pathak, N., Patino, C. A., Bao, G., & Espinosa, H. D. (2022) · ACS Nano · doi:10.1021/acsnano.2c05494 · Cited by 20
Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
Atar, D., Mast, A., Scheuermann, S., Ruoff, L., Seitz, C. M., & Schlegel, P. (2022) · Biomedicines · doi:10.3390/biomedicines10102420 · Cited by 20
Harrer, D. C., Schenkel, C., Berking, C., Herr, W., Abken, H., Dörrie, J., & Schaft, N. (2022) · Cancers · doi:10.3390/cancers14205033 · Cited by 20
Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox
Xiao, J., Zhang, T., Gao, F., Zhou, Z., Shu, G., Zou, Y., & Yin, G. (2022) · Cancers · doi:10.3390/cancers14225657 · Cited by 19
Chakraborty, A., Roy, G., Swami, B., & Bhaskar, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109463 · Cited by 20
Kalluri, A. L., Shah, P. P., & Lim, M. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032020 · Cited by 22
Chakraborty, R., Darido, C., Liu, F., Maselko, M., & Ranganathan, S. (2023) · Cancers · doi:10.3390/cancers15030852 · Cited by 20
New insights into the Lck-NF-κB signaling pathway
Zhang, J., Wu, Y., Hu, X., & Wei, W. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1120747 · Cited by 21
Therapeutic utility of engineered myeloid cells in the tumor microenvironment
Canella, A., & Rajappa, P. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00600-7 · Cited by 20
Yu, Y., Wu, Y., Zhang, Y., Lu, M., & Su, X. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13630 · Cited by 20
Pediatric Brain Tumours: Lessons from the Immune Microenvironment
Yao, B., Delaidelli, A., Vogel, H. S., & Sorensen, P. H. B. (2023) · Current Oncology · doi:10.3390/curroncol30050379 · Cited by 21
Hänsch, L., Peipp, M., Mastall, M., Villars, D., Myburgh, R., Silginer, M., Weiß, T., Gramatzki, D., Vasella, F., Manz, M. G., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad108 · Cited by 21
In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy
Śledź, M., Wojciechowska, A., Zagożdżon, R., & Kaleta, B. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00683-y · Cited by 21
Shakhpazyan, N. K., Михалева, Л. М., Bedzhanyan, A. L., Владиславовна, Г. З., Sadykhov, N. K., Mikhalev, A., Atiakshin, D., Buchwalow, I., Tiemann, M., & Orekhov, A. N. (2023) · Biomedicines · doi:10.3390/biomedicines11092361 · Cited by 20
Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid‐Based Nanoparticles
Fernandes, S., Cassani, M., Cavalieri, F., Forte, G., & Caruso, F. (2023) · Advanced Science · doi:10.1002/advs.202305769 · Cited by 20
Dai, Z., Lin, X., Wang, X., Zou, X., Yan, Y. H., Wang, R., Chen, Y., Tasiheng, Y., Ma, M., Wang, X., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03648-y · Cited by 20
Current Strategies to Improve Chimeric Antigen Receptor T (CAR-T) Cell Persistence
Ghorai, S. K., & Pearson, A. N. (2024) · Cureus · doi:10.7759/cureus.65291 · Cited by 23
Magrath, J. W., Espinosa-Cotton, M. M., Flinchum, D. A., Sampath, S. S., Cheung, N. V., & Lee, S. B. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1442488 · Cited by 23
The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches
Polychronopoulos, P. A., Bedoya-Reina, O. C., & Johnsen, J. I. (2024) · Cancers · doi:10.3390/cancers16101863 · Cited by 19
Wu, M., Valença-Pereira, F., Cendali, F. I., Giddings, E. L., Pham‐Danis, C., Yarnell, M. C., Novak, A. J., Brunetti, T. M., Thompson, S. B., Henao‐Mejia, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48653-y · Cited by 22
Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function
Schuurmans, F., Wagemans, K. E., Adema, G. J., & Cornelissen, L. A. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1409238 · Cited by 20
Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review
Shebrain, A., Idris, O. A., Jawad, A., Zhang, T., & Xing, Y. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185409 · Cited by 19
Gavrilescu, M. C. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.157152 · Cited by 22
Improving systemic delivery of oncolytic virus by cellular carriers
Peng, Z., Kalim, M., & Lu, Y. (2025) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0390 · Cited by 21
Giri, S., Lamichhane, G., Pandey, J., Khadayat, R., Sindhu, K. C., Devkota, H. P., & Khadka, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072923 · Cited by 22
Menon, A. V., Song, B., Chao, L., Sriram, D., Chansky, P. A., Bakshi, I., Ulianova, J., & Li, W. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1565387 · Cited by 21
Dumitru, I. G., Todor, S. B., Ichim, C., Helgiu, C., & Helgiu, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14092982 · Cited by 25
Yang, D. D., Macmorland, W., & Arnold, J. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643941 · Cited by 22
Optimizing mitochondria function in immune cells: implications for cancer immunotherapy
Li, H., Jin, W., Liu, J., Zhou, Y., Shan, X., Zhang, Y., Kou, Y., Deng, C., Jin, C., Kuang, J., et al. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.006 · Cited by 19
Emerging EGFR-Targeted Therapy in Head and Neck Cancer
Hwang, W., Ahn, J. S., Jung, H. A., Wirth, L. J., & Park, J. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.3136 · Cited by 19
Methods for the directed evolution of biomolecular interactions
Xie, V. C., Styles, M. J., & Dickinson, B. C. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.01.001 · Cited by 19
Scratching the Surface—An Overview of the Roles of Cell Surface GRP78 in Cancer
Chen, J., Lynn, E. G., Yousof, T. R., Sharma, H., MacDonald, M. E., Byun, J. H., Shayegan, B., & Austin, R. C. (2022) · Biomedicines · doi:10.3390/biomedicines10051098 · Cited by 19
Adverse Renal Effects of Anticancer Immunotherapy: A Review
Borówka, M., Łącki-Zynzeling, S., Nicze, M., Kozak, S., & Chudek, J. T. (2022) · Cancers · doi:10.3390/cancers14174086 · Cited by 22
Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future
Minaei, N., Ramezankhani, R., Tamimi, A., Piryaei, A., Zarrabi, A., Aref, A. R., Mostafavi, E., & Vosough, M. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151284 · Cited by 19
Acosta‐Medina, A. A., Johnson, I. M., Bansal, R., Hathcock, M. A., Kenderian, S. S., Durani, U., Khurana, A., Wang, Y., Paludo, J., Villasboas, J. C., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-022-00777-4 · Cited by 19
Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors
Wang, X., Meng, F., Li, X., Xue, L., Chen, A., Qiu, Y., Zhang, Z., Li, L., Liu, F., Li, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202205044 · Cited by 21
Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine
Casado, P., & Cutillas, P. R. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100517 · Cited by 19
Challenges and optimal strategies of CAR T therapy for hematological malignancies
Zhang, Y., Yang, X., Dang, X., Zhu, Z., Qian, W., Liang, A., & Han, W. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002476 · Cited by 19
Eyre, T. A., Hess, L. M., Sugihara, T., He, D., Khanal, M., Pagel, J. M., Walgren, R. A., Abada, P., Koenig, H., Roeker, L. E., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2190436 · Cited by 20
Jin, Z., Xiang, R., Qing, K., Li, D., Liu, Z., Li, X., Zhu, H., Zhang, Y., Wang, L., Xue, K., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00833-6 · Cited by 19
Wang, H., Tang, L. Y., Kong, Y., Liu, W., Zhu, X., & You, Y. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119115 · Cited by 19
Harnessing neutrophil plasticity for HCC immunotherapy
Ramon‐Gil, E., Geh, D., & Leslie, J. (2023) · Essays in Biochemistry · doi:10.1042/ebc20220245 · Cited by 19
Dougé, A., El-Ghazzi, N., Lemal, R., & Rouzaire, P. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0310 · Cited by 21
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
Cao, J., Zhang, Z., Zhou, L., Luo, M., Li, L., Li, B., Nice, E. C., He, W., Zheng, S., & Huang, C. (2023) · MedComm · doi:10.1002/mco2.427 · Cited by 19
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
Giraudo, M. F., Jackson, Z., Das, I., Abiona, O. M., & Wald, D. N. (2024) · Pathogens and Immunity · doi:10.20411/pai.v9i1.647 · Cited by 19
In vivo manufacture and manipulation of CAR-T cells for better druggability
Hou, R., Zhang, X., Wang, X., Zhao, X., Li, S., Guan, Z., Cao, J., Liu, D., Zheng, J., & Shi, M. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10185-8 · Cited by 32
Guijarro-Albaladejo, B., Marrero-Cepeda, C., Arboli, E. R., Sierro-Martínez, B., Pérez‐Simón, J. A., & García‐Guerrero, E. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1376554 · Cited by 20
Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies
Tsiverioti, C. A., Gottschlich, A., Trefny, M. P., Theurich, S., Anders, H., Kroiß, M., & Kobold, S. (2024) · Biological Chemistry · doi:10.1515/hsz-2023-0317 · Cited by 20
Elmarasi, M., Elkonaissi, I., Elsabagh, A., Elsayed, E., Elsayed, A., Elsayed, B., Elmakaty, I., & Yassin, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112312 · Cited by 16
Cho, Y., Laird, M. S., Bishop, T., Li, R., Jazwinska, D. E., Ruffo, E., Lohmueller, J. J., & Zervantonakis, I. K. (2024) · APL Bioengineering · doi:10.1063/5.0207941 · Cited by 19
Thrombotic complications after hematopoietic stem cell transplantation and other cellular therapies
Evangelidis, P., Gavriilaki, E., & Tsakiris, D. Α. (2024) · Thrombosis Update · doi:10.1016/j.tru.2024.100186 · Cited by 19
Ding, M., Lin, J., Qin, C., Fu, Y., Du, Y., Qiu, X., Wei, P., & Xu, T. (2024) · Advanced Science · doi:10.1002/advs.202400156 · Cited by 20
CAR-T Cells Targeting Immune Checkpoint Pathway Players
Golubovskaya, V. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2704121 · Cited by 19
Current State of Cell Therapies for Breast Cancer
Gautam, N., Elleson, K. M., Ramamoorthi, G., & Czerniecki, B. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000607 · Cited by 19
Kara, E., Jackson, T. L., Jones, C., Sison, R., & McGee, R. L. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00435-4 · Cited by 18
Nanomaterial-based cancer immunotherapy: enhancing treatment strategies
Tian, M., Liu, X., & Pei, H. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1492215 · Cited by 18
Metadata
- Authors
- Sterner, R. C., & Sterner, R. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Sterner, Rosalie M.
- Venue
- Blood Cancer Journal
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 4
- Pages
- 69-69
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8024391
- OpenAlex
- W3148729173
- Cited by
- 2,926
- References
- 110
- Citations by year
- 2026: 530 · 2025: 806 · 2024: 726 · 2023: 532 · 2022: 287 · 2021: 42
- FWCI
- 48.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Wisconsin-Madison (T32-GM008692)
- Regenerative Medicine Minnesota (RMM 012819 EPC 003)
- National Institute of General Medical Sciences (T32GM008692)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, chimeric antigen receptor, solid tumors, hematologic malignancies, CAR-T cell engineering, tumor microenvironment, antigen escape, CAR-T toxicity, tumor infiltration
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Hematologic Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
